Coronary Artery DiseaseDestinACSionNCT07190690
Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
A study testing ihtDEStiny® DES implanted and Xience™ DES implanted in people with Coronary Artery Disease, run by Fundación EPIC at 20 sites in Spain.
Trial summary
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention). To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- ihtDEStiny® DES implanted and Xience™ DES implanted
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,100 participants
- Where
- 20 sitesSpain
- Study dates
- 19 Dec 2025to 15 Oct 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who meet ALL inclusion criteria will be included:
- Patients aged ≥18 years, and
- Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and
- Patients with de novo lesions in vessels with a reference diameter of ≥2.25 mm and ≤4.5 mm in whom implantation of one or more DES is clinically indicated, and
- Patients who have been informed of the characteristics of the study and have provided written informed consent.
Who cannot join
- Patients must not meet any of the following exclusion criteria:
- Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): "C" (Classic Shock), "D" (Deteriorating) and "E" (Extremis).
- Patients unable to provide informed consent.
- Patients with a known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES.
- Patients with active bleeding at the time of PCI requiring medical attention.
- Patients with planned surgery within the next 3 months.
Show all 9Show fewer
- Patients with any medical condition that limits a life expectancy of less than 12 months.
- Patients participating in another clinical trial in which the primary endpoint was not met.
- Pregnant or breastfeeding women of childbearing potential with a positive pregnancy test.
Trial locations and contacts
20 sites in 1 country. Contact the study team or a site near you to ask about taking part.
20 sites in 1 country
Spain20 sites, 20 recruiting
- Recruiting
Hospital Universitario San Juan Alicante
Alicante, 03550
- Recruiting
Hospital Universitari Germans Trias I Pujol
Badalona, 08916
- Recruiting
Hospital Universitario de Cruces
Barakaldo, 48903
- Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, 08035
- Recruiting
Hospital Clínic de Barcelona
Barcelona, 08036
- Recruiting
Hospital General Universitario de Castellon
Castelló, 12004
- Recruiting
Hospital Universitario de Donostia
Donostia / San Sebastian, 20014
- Recruiting
Hospital Universitario Virgen de La Arrixaca
El Palmar, 30120
- Recruiting
Hospital Universitario La Paz
Fuencarral-El Pardo, 28046
- Recruiting
Hospital Universitario Juan Ramón Jiménez
Huelva, 21005
- Recruiting
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, 08907
- Recruiting
Hospital Universitario de Leon
León, 24008
- Recruiting
Hospital Universitari Arnau de Vilanova
Lleida, 25198
- Recruiting
Hospital Universitario Lucus Agustí
Lugo, 27003
- Recruiting
Hospital Regional Universitario de Málaga
Málaga, 29010
- Recruiting
Hospital Universitario de Canarias
San Cristóbal de La Laguna, 38320
- Recruiting
Hospital Universitario Marques de Valdecilla
Santander, 39008
- Recruiting
Hospital Clínico Universitario de Santiago
Santiago de Compostela, 15706
- Recruiting
Hospital Universitari de Tarragona Joan XXIII
Tarragona, 43005
- Recruiting
Hospital Clínico Universitario Lozano Blesa
Zaragoza, 50009
About this study
Official title: Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (DestinACSion Study)
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).
To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.
Read the detailed description
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).
To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.
- Conditions
- Coronary Artery Disease
- Being tested
- ihtDEStiny® DES implanted, Xience™ DES implanted
- Keywords
- Drug Eluting Stents
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ihtDEStiny® DES implantedDevice
ihtDEStiny® DES implanted
Xience™ DES implantedDevice
Xience™ DES implanted
| Study group | Role | What they receive |
|---|---|---|
| Active Comparator: ihtDEStiny® DES | Other | Not described Receives: Device: ihtDEStiny® DES implanted |
| Experimental: Xience™ DES | Other | Not described Receives: Device: Xience™ DES implanted |
What is being measured
The primary outcome is the main question the study is designed to answer.
EFFICACY: Device-oriented Composite Endpoint (DoCE)
Composite clinical endpoint cardiac Rate at 12 months cause death, target vessel myocardial infraction (TV-MI), and Clinically individual target lesion revascularization (CI-TLR)
Measured: 12 months
NACE
Composite clinical endpoint Rate of all-cause death, any stroke, any MI, any revascularization and BARC type 3 or 5 bleeding events
Measured: 12 months
Secondary outcomes (27)
All-Cause Death Rate at 12 months
All-Cause Death Rate at 12 months
Measured: 12 months
All-Cause Death Rate at 24 months
All-Cause Death Rate at 24 months
Measured: 12 months
Cardiac Death Rate at 12 months
Cardiac Death Rate at 12 months
Measured: 12 months
Cardiac Death Rate at 24 months
Cardiac Death Rate at 24 months
Measured: 12 months
Myocardial Infarction Rate at 12 months
Myocardial Infarction Rate at 12 months
Measured: 12 months
Myocardial Infarction Rate at 24 months
Myocardial Infarction Rate at 24 months
Measured: 12 months
Periprocedural myocardial infarction Rate
Periprocedural myocardial infarction Rate
Measured: PCI procedure
Definite/Probable stent thrombosis rate at 12 months
Definite/Probable stent thrombosis rate at 12 months
Measured: 12 months
Definite/Probable stent thrombosis rate at 24 months
Definite/Probable stent thrombosis rate at 24 months
Measured: 24 months
Any stroke at 12 months
Stroke Rate at 12 months
Measured: 12 months
Any stroke at 24 months
Stroke Rate at 24 months
Measured: 12 months
BARC type 2 ,3 or 5 bleeding events at 12 months
Bleeding events type 2, 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria at 12 months
Measured: 12 months
BARC type 2 ,3 or 5 bleeding events at 24 months
Bleeding events type 2, 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria at 24 months
Measured: 24 months
Target vessel revascularization Rate at 12 months
Target vessel revascularization Rate at 12 months
Measured: 12 months
Target vessel revascularization Rate at 24 months
Target vessel revascularization Rate at 24 months
Measured: 24 months
Target vessel Failure (TVF) Rate at 12 months
Target vessel Failure (TVF) Rate at 12 months
Measured: 12 months
Target vessel Failure (TVF) Rate at 24 months
Target vessel Failure (TVF) Rate at 24 months
Measured: 24 months
Target Lesion Failure (TLF) Rate at 12 months
Target Lesion Failure (TLF) Rate at 12 months
Measured: 12 months
Target Lesion Failure (TLF) Rate at 24 months
Target Lesion Failure (TLF) Rate at 24 months
Measured: 24 months
Target Vessel Revascularization Rate (TVR) at 12 months
Target Vessel Revascularization Rate (TVR) at 12 months
Measured: 12 months
Target Vessel Revascularization Rate (TVR) at 24 months
Target Vessel Revascularization Rate (TVR) at 24 months
Measured: 24 months
Target lesion ischemia-guided revascularization Rate at 12 months
Target lesion ischemia-guided revascularization Rate at 12 months
Measured: 12 months
Target lesion ischemia-guided revascularization Rate at 24 months
Target lesion ischemia-guided revascularization Rate at 24 months
Measured: 24 months
Repeated revascularization Rate at 12 months
Repeated revascularization Rate at 12 months
Measured: 12 months
Repeated revascularization Rate at 24 months
Repeated revascularization Rate at 24 months
Measured: 24 months
Major Adverse Cardiac Events (MACE) Rate at 12 months
Major Adverse Cardiac Events (MACE) Rate is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization at 12 months
Measured: 12 months
Major Adverse Cardiac Events (MACE) Rate at 24 months
Major Adverse Cardiac Events (MACE) Rate is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization at 24 months
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2025
- Study start19 Dec 2025
- Primary completion15 Oct 2029 (estimated)
- Study completion15 Oct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2,100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundación EPIC
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07190690
- Sponsor's protocol ID
- EPIC45-DestinACSion
- Acronym
- DestinACSion
- Status last verified
- Aug 2026
- First submitted
- 17 Sep 2025
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
de la Torre Hernandez JM, Otaegui I, Subinas A, Gomez-Menchero A, Moreno R, Rondan J, Munoz-Garcia E, Sainz-Laso F, Garcia Del Blanco B, Rumoroso JR, Diaz JF, Berenguer A, Gomez-Lara J, Zueco J. First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study. Cardiovasc Revasc Med. 2021 Nov;32:18-24. doi: 10.1016/j.carrev.2020.12.025. Epub 2020 Dec 29.
PubMed 33386256Ploumen EH, von Birgelen C. Novel DES Aims at Full Thromboresistance: Another Promising Player on the Field? Cardiovasc Revasc Med. 2021 Nov;32:25-26. doi: 10.1016/j.carrev.2021.07.029. Epub 2021 Aug 11. No abstract available.
PubMed 34391680Linares Vicente JA, Sainz Laso F, Casanova Sandoval JM, Rumoroso Cueva JR, Gomez Menchero A, Gomez Hospital JA, Perez Guerrero A, Santos Martinez S, Fernandez Portales J, Romani S, Garcia Del Blanco B, Ocaranza Sanchez R, Urbano Carrillo C, Garcia San Roman K, Vinhas H, Cid Alvarez B, Sanchis Fores J, Telleria Arrieta M, Torres Bosco A, Pinar Bermudez E, Mendez Castro JJ, Lozano Ruiz de Poveda F, Perez de Prado A, De la Torre Hernandez JM. Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VELAZQUEZ-EPIC26 study. Cardiovasc Revasc Med. 2026 Mar;84:26-33. doi: 10.1016/j.carrev.2025.07.009. Epub 2025 Jul 17.
PubMed 40713212Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28.
PubMed 30827782Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289.
PubMed 29891620
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (DestinACSion Study)
- ClinicalTrials.gov ID
- NCT07190690
- Acronym / sponsor ID
- DestinACSion / EPIC45-DestinACSion
- Conditions
- Coronary Artery Disease
- Keywords
- Drug Eluting Stents
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,100 participants (estimated)
- Lead sponsor
- Fundación EPICUniversity, hospital or other
- Study start
- 19 Dec 2025 (actual)
- Primary completion
- 15 Oct 2029 (estimated)
- Study completion
- 15 Oct 2030 (estimated)
- First posted
- 24 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).
To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.
Detailed description
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).
To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active Comparator: ihtDEStiny® DES | Other | Device: ihtDEStiny® DES implanted |
| Experimental: Xience™ DES | Other | Device: Xience™ DES implanted |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients aged ≥18 years, and
- Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and
- Patients with de novo lesions in vessels with a reference diameter of ≥2.25 mm and ≤4.5 mm in whom implantation of one or more DES is clinically indicated, and
- Patients who have been informed of the characteristics of the study and have provided written informed consent.
Key exclusion criteria (9 listed)
- Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): "C" (Classic Shock), "D" (Deteriorating) and "E" (Extremis).
- Patients unable to provide informed consent.
- Patients with a known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES.
- Patients with active bleeding at the time of PCI requiring medical attention.
- Patients with planned surgery within the next 3 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ihtDEStiny® DES implantedihtDEStiny® DES implanted | Device | Active Comparator: ihtDEStiny® DES |
| Xience™ DES implantedXience™ DES implanted | Device | Experimental: Xience™ DES |
Primary outcome
EFFICACY: Device-oriented Composite Endpoint (DoCE)
Time frame: 12 months
Composite clinical endpoint cardiac Rate at 12 months cause death, target vessel myocardial infraction (TV-MI), and Clinically individual target lesion revascularization (CI-TLR)
NACE
Time frame: 12 months
Composite clinical endpoint Rate of all-cause death, any stroke, any MI, any revascularization and BARC type 3 or 5 bleeding events
27 secondary outcomes
All-Cause Death Rate at 12 months
Time frame: 12 months
All-Cause Death Rate at 24 months
Time frame: 12 months
Cardiac Death Rate at 12 months
Time frame: 12 months
Cardiac Death Rate at 24 months
Time frame: 12 months
Myocardial Infarction Rate at 12 months
Time frame: 12 months
Myocardial Infarction Rate at 24 months
Time frame: 12 months
Periprocedural myocardial infarction Rate
Time frame: PCI procedure
Definite/Probable stent thrombosis rate at 12 months
Time frame: 12 months
Definite/Probable stent thrombosis rate at 24 months
Time frame: 24 months
Any stroke at 12 months
Time frame: 12 months
Any stroke at 24 months
Time frame: 12 months
BARC type 2 ,3 or 5 bleeding events at 12 months
Time frame: 12 months
BARC type 2 ,3 or 5 bleeding events at 24 months
Time frame: 24 months
Target vessel revascularization Rate at 12 months
Time frame: 12 months
Target vessel revascularization Rate at 24 months
Time frame: 24 months
Target vessel Failure (TVF) Rate at 12 months
Time frame: 12 months
Target vessel Failure (TVF) Rate at 24 months
Time frame: 24 months
Target Lesion Failure (TLF) Rate at 12 months
Time frame: 12 months
Target Lesion Failure (TLF) Rate at 24 months
Time frame: 24 months
Target Vessel Revascularization Rate (TVR) at 12 months
Time frame: 12 months
Target Vessel Revascularization Rate (TVR) at 24 months
Time frame: 24 months
Target lesion ischemia-guided revascularization Rate at 12 months
Time frame: 12 months
Target lesion ischemia-guided revascularization Rate at 24 months
Time frame: 24 months
Repeated revascularization Rate at 12 months
Time frame: 12 months
Repeated revascularization Rate at 24 months
Time frame: 24 months
Major Adverse Cardiac Events (MACE) Rate at 12 months
Time frame: 12 months
Major Adverse Cardiac Events (MACE) Rate at 24 months
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Background: PubMed 33386256de la Torre Hernandez JM, Otaegui I, Subinas A, Gomez-Menchero A, Moreno R, Rondan J, Munoz-Garcia E, Sainz-Laso F, Garcia Del Blanco B, Rumoroso JR, Diaz JF, Berenguer A, Gomez-Lara J, Zueco J. First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study. Cardiovasc Revasc Med. 2021 Nov;32:18-24. doi: 10.1016/j.carrev.2020.12.025. Epub 2020 Dec 29.
- Background: PubMed 34391680Ploumen EH, von Birgelen C. Novel DES Aims at Full Thromboresistance: Another Promising Player on the Field? Cardiovasc Revasc Med. 2021 Nov;32:25-26. doi: 10.1016/j.carrev.2021.07.029. Epub 2021 Aug 11. No abstract available.
- Background: PubMed 40713212Linares Vicente JA, Sainz Laso F, Casanova Sandoval JM, Rumoroso Cueva JR, Gomez Menchero A, Gomez Hospital JA, Perez Guerrero A, Santos Martinez S, Fernandez Portales J, Romani S, Garcia Del Blanco B, Ocaranza Sanchez R, Urbano Carrillo C, Garcia San Roman K, Vinhas H, Cid Alvarez B, Sanchis Fores J, Telleria Arrieta M, Torres Bosco A, Pinar Bermudez E, Mendez Castro JJ, Lozano Ruiz de Poveda F, Perez de Prado A, De la Torre Hernandez JM. Long-term outcomes of hydrodynamic ultra-thin strut sirolimus-eluting stent with fluoropolymer containing triflusal: VELAZQUEZ-EPIC26 study. Cardiovasc Revasc Med. 2026 Mar;84:26-33. doi: 10.1016/j.carrev.2025.07.009. Epub 2025 Jul 17.
- Background: PubMed 30827782Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28.
- Background: PubMed 29891620Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ihtDEStiny® DES implanted and Xience™ DES implanted in people with Coronary Artery Disease, run by Fundación EPIC at 20 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Armando Pérez de Prado, MD, PhD (0034987876135, admin@fundacionepic.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
EFFICACY: Device-oriented Composite Endpoint (DoCE) (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07190690, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.